Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | RGS12 | O14924 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1000171 | 0.82 | GAA (0.55) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL17926089 | 0.81 | FFAR1 (0.54) | POLBHIF1AALDH1A1CA2THRA | |
| SCHEMBL8990620 | 0.79 | PCNA (0.48) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL7974514 | 0.79 | ALDH1A1 (0.64) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL16179546 | 0.78 | GAA (0.52) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL6377974 | 0.78 | GAA (0.68) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL8510463 | 0.78 | HPGD (0.68) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL30716576 | 0.78 | HPGD (0.68) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL2434720 | 0.77 | GAA (0.50) | HPGDHSD17B10GAAKDM4ETSHR | |
| SCHEMBL2597844 | 0.77 | CA2 (0.65) | HPGDHSD17B10GAAKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237396-B1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2019-07-03 | — | — | EP | disclosed |
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-9902725-B2 | Heterocyclic derivatives as RORgamma modulators | GENFIT (FR) | 2018-02-27 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2017-12-07 | — | — | US | disclosed |
| EP-3237396-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | Genfit (FR) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016102633-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | GENFIT (FR) | 2016-06-30 | — | — | WO | disclosed |
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2632464-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349582-A1 | HETEROCYCLIC DERIVATIVES AS RORGAMMA MODULATORS | RORC, RORB, RORA | HPGD 1011/4885HSD17B10 753/4885GAA 2392/4885 |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | HPGD 1503/4885HSD17B10 3153/4885GAA 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.